Amicus Therapeutics Company Insiders

Amicus Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of 0.0249 % which means that it generated a profit of $0.0249 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1158) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.05, whereas Return On Tangible Assets are forecasted to decline to (0.04). At present, Amicus Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.36, whereas Other Assets are forecasted to decline to about 41.8 M. The current year's Common Stock Shares Outstanding is expected to grow to about 323.8 M, whereas Net Loss is forecasted to decline to (223.6 M). The majority of Amicus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amicus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amicus Therapeutics. Please pay attention to any change in the institutional holdings of Amicus Therapeutics as this could imply that something significant has changed or is about to change at the company. Some institutional investors establish a significant position in stocks such as Amicus Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Amicus Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Amicus Therapeutics Workforce Comparison

The company has Profit Margin (PM) of (0.04) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.09 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.09.

Amicus Therapeutics Insider Trading History

Amicus Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Amicus Therapeutics often depends on how effective the management is. Amicus Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amicus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amicus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Amicus Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amicus Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Amicus Therapeutics' management manipulating its earnings.

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.